Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Freegold Intersects 3.62 g/t Au over 42m and 1.23 g/t Au over 170.7m (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Renalytix American Depository Receipt RNLXY

Healthcare Medical Devices
Renalytix plc is a United Kingdom-based company, which is engaged in the development of artificial intelligence-enabled clinical diagnostic solutions for kidney disease. The Company is engaged in a field of bioprognosis for kidney health. The Company has engineered a solution that enables early-stage chronic kidney disease progression risk assessment. The Company’s lead product, KidneyIntelX... see more

Recent & Breaking News (OTCQB:RNLXY)

Commencement of trading on OTCQB in the United States

GlobeNewswire October 8, 2024

Renalytix and Steno Diabetes Center Announce Precision Medicine Collaboration Marking First Expansion for KidneyIntelX Platform Beyond US

GlobeNewswire July 11, 2024

Renalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting Determination

GlobeNewswire June 27, 2024

Medicare Issues Final Coverage Determination for kidneyintelX.dkd

GlobeNewswire June 14, 2024

Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2024

GlobeNewswire May 15, 2024

Renalytix to Report Financial Results for Third Quarter Fiscal Year 2024 on May 15

GlobeNewswire May 9, 2024

Renalytix Announces Financing with Expected Size of up to $4 Million

GlobeNewswire April 8, 2024

KidneyIntelX(TM) included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD)

GlobeNewswire March 14, 2024

Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2024

GlobeNewswire February 15, 2024

Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

GlobeNewswire February 9, 2024

New published data demonstrates KidneyIntelX(TM) has broad implications for winning war on chronic kidney disease

GlobeNewswire January 10, 2024

Renalytix Reports Financial Results for First Quarter of Fiscal Year 2024

GlobeNewswire November 14, 2023

Renalytix to Report Financial Results for First Quarter Fiscal Year 2024 on November 14

GlobeNewswire November 7, 2023

US Patent Office Allows Patent Claims for Intellectual Property Exclusively Licensed to Renalytix

GlobeNewswire October 6, 2023

Renalytix Reports Full Year Fiscal 2023 Results

GlobeNewswire September 28, 2023

Renalytix to Report Financial Results for Fourth Quarter and Full Year Fiscal 2023 on September 28

GlobeNewswire September 25, 2023

Renalytix Appoints Senior Executive Howard Doran as Chief Business Officer

GlobeNewswire September 7, 2023

Renalytix Clinical Advisory Board Formed to Support Broadening Use of KidneyintelX.dkd

GlobeNewswire August 3, 2023

Renalytix Announces Middle East Distribution Agreement with Vector Pharma

GlobeNewswire July 21, 2023

Late-Breaking KidneyIntelX Evidence Released at 83rd American Diabetes Association Scientific Sessions

GlobeNewswire July 7, 2023